We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Sorrento Therapeutics Inc (SRNE) is a leading biotechnology business with stocks listed in the US. It opened the day at US$8.72 after a previous close of US$8.87. During the day the price has varied from a low of USD8.35 to a high of USD8.83. The latest price was USD8.69 (25 minute delay). Sorrento Therapeutics is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| Open | US$8.72 |
|---|---|
| High | US$8.83 |
| Low | US$8.35 |
| Close | US$8.69 |
| Previous close | US$8.87 |
| Change | US$-0.18 |
| Change % | -2.0293% |
| Volume | 4,256,938 |
| 52-week range | US$6 - US$17.25 |
|---|---|
| 50-day moving average | US$7.7306 |
| 200-day moving average | US$8.1025 |
| Target price | US$26.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.175 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $8.69
| 1 month (2021-09-16) | 7.55% |
|---|---|
| 3 months (2021-07-16) | 9.58% |
| 6 months (2021-04-16) | 16.02% |
| 1 year (2020-10-16) | -6.56% |
|---|---|
| 2 years (2019-10-16) | 402.31% |
| 3 years (2018-10-16) | 136.14% |
| 5 years (2016-10-14) | 22.57% |
| Revenue TTM | US$51 million |
|---|---|
| Gross profit TTM | US$-81,294,000 |
| Return on assets TTM | -27.49% |
| Return on equity TTM | -244.23% |
| Profit margin | 0% |
| Book value | 0.641 |
| Market capitalisation | US$2.1 billion |
TTM: trailing 12 months
There are currently 45.7 million Sorrento Therapeutics shares held short by investors – that's known as Sorrento Therapeutics's "short interest". This figure is 6% up from 43.1 million last month.
There are a few different ways that this level of interest in shorting Sorrento Therapeutics shares can be evaluated.
Sorrento Therapeutics's "short interest ratio" (SIR) is the quantity of Sorrento Therapeutics shares currently shorted divided by the average quantity of Sorrento Therapeutics shares traded daily (recently around 4.3 million). Sorrento Therapeutics's SIR currently stands at 10.51. In other words for every 100,000 Sorrento Therapeutics shares traded daily on the market, roughly 10510 shares are currently held short.
However Sorrento Therapeutics's short interest can also be evaluated against the total number of Sorrento Therapeutics shares, or, against the total number of tradable Sorrento Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sorrento Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Sorrento Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1705% of the tradable shares (for every 100,000 tradable Sorrento Therapeutics shares, roughly 171 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Sorrento Therapeutics.
Find out more about how you can short Sorrento Therapeutics stock.
We're not expecting Sorrento Therapeutics to pay a dividend over the next 12 months.
Sorrento Therapeutics's shares were split on a 1:25 basis on 31 July 2013. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therapeutics shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therapeutics shares which in turn could have impacted Sorrento Therapeutics's share price.
Over the last 12 months, Sorrento Therapeutics's shares have ranged in value from as little as US$6 up to US$17.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therapeutics's is 2.4032. This would suggest that Sorrento Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patients with melanoma; and Karolinska Institutet. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Shares in the insurer are up just 10% in the last 12 months.
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
The payment services company’s shares are up 16% in the last year.
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
